about
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.Novel and simple transformation algorithm for combining microarray data sets.Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in KoreaSunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.Identification of significant regional genetic variations using continuous CNV values in aCGH data.An attempt for combining microarray data sets by adjusting gene expressionsDifferential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trialsPrevalence and prognostic implications of psychological distress in patients with gastric cancer.S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumabQuality of life in the trastuzumab for gastric cancer trialComplementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancerRegions of allelic imbalance in the distal portion of chromosome 12q in gastric cancerHigh KLF4 level in normal tissue predicts poor survival in colorectal cancer patientsRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerIdentification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experienceClinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites.The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progressionIncidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and ChildrenInflammatory and tumor stimulating responses after laparoscopic sigmoidectomy.Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.LAMC2 enhances the metastatic potential of lung adenocarcinoma.Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: a case report and review of the literature.Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
P50
Q27853081-DADFB280-D9FF-44EA-B323-CE7EBE2B5475Q31116686-5FE49AF2-89C7-45F8-9625-2E042994F0C2Q33365840-2BC5AFA7-19C2-4316-93B3-04E5FBCD7857Q33375134-2445539E-CA9B-441C-859A-B1AFEDB62FE5Q33385981-95E16D53-37D0-4BFE-BC1D-80749407E823Q33396613-6656CB6B-1444-4016-891B-00A1E71B1CECQ33399177-5C87C1A5-DBC9-46DD-8ABC-24BC328194E5Q33413523-08832535-6847-430F-9E37-1B378546DDA2Q33413566-BA51BC7E-F0B2-414C-82B1-07351F20B0DAQ33423800-A46AE30B-5DE4-43E6-9E09-6809DCC9ACF6Q33440401-896F0441-41A0-4E3F-9172-4C3C5E2EE736Q33495849-FCE8242B-E902-4357-9162-B376D3FF1233Q33502227-63AB1878-FDDD-4B84-9828-38CBC0973D7EQ33557905-8C0BAB16-9A5F-464F-BF6A-1D262E1841F1Q33566877-AF8CD321-9A70-4ACD-AF28-C4F6AE978F13Q33576276-F345AC1D-9A55-4D7F-B650-877A0B7CCA48Q33587575-6C1104FA-FB2A-4D3A-853A-A68C1F31F716Q33643492-24C5F96E-B1B2-4A21-AE12-C305264D9D84Q33761681-D8DD6BF0-213A-4F79-8BA7-301C0F49467AQ33829785-AFB973FB-3FD4-4801-BBA4-E0FD3BD1E3E2Q33888813-FB72F70C-F825-4F49-8D13-E765698A27A7Q33919180-269904E4-A48B-4EBF-867D-D067297EF415Q33990397-D30412FF-4B5C-4C54-8DD0-75904AF299C3Q34327051-C2EF3B3E-DD77-4D55-B73A-3BF26233EF94Q34356765-499D18C3-536D-4291-B097-FB4F637A053DQ34428153-0928604E-B876-4C49-B2AB-ADA8A3F10708Q34444374-8AE2C222-456C-40F1-8EDF-574887F98112Q34494770-E2AE1441-6DC7-4AA1-A413-EB01B24CE565Q34646724-07D4B610-0574-477A-B890-86CA317001C9Q34977196-84143D36-83FF-408A-84BF-0CC5B4F08F18Q35014804-C5A9B409-DAC5-48B6-AB64-7781B194D8D9Q35233550-39981F8F-B059-41DB-A83A-5EDA7FDA614AQ35829871-AB2EF9C9-901E-48F9-B350-FA66E4E3D30FQ36072022-FC3F4AD1-B038-42DD-B4B3-CC26069B61ACQ36187013-6DBEF88A-0A6D-4257-B8E4-8847F8E930AFQ36194009-C8AC446E-B0EC-48AE-A787-AA1A121FBCAAQ36484436-32C655F7-97A5-40A0-89E9-7C82945909CCQ36500021-26C9EA39-652F-4718-BD54-3E81C3F34EA6Q36612624-38FF8AA8-7113-47AF-9622-E656AABCA08AQ36832144-D0AEA3DC-589D-4147-8DF9-73151F27EA45
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0920-9471
@en
name
Hyun Cheol Chung
@ast
Hyun Cheol Chung
@en
Hyun Cheol Chung
@es
Hyun Cheol Chung
@nl
type
label
Hyun Cheol Chung
@ast
Hyun Cheol Chung
@en
Hyun Cheol Chung
@es
Hyun Cheol Chung
@nl
prefLabel
Hyun Cheol Chung
@ast
Hyun Cheol Chung
@en
Hyun Cheol Chung
@es
Hyun Cheol Chung
@nl
P106
P31
P496
0000-0002-0920-9471